Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1617 participants.
Also called NCT03400800
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,617 participants
- Sponsor
- Registry
-
NCT03400800
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Czechia, Germany, Hungary, Poland, South Africa, Ukraine, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03400800. Randomized; double masking; primary purpose treatment. Start 2017-11-01 (actual); primary completion 2019-07-31 (actual). Results posted on 2020-08-21.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Inclisiran for Subjects With ASCVD or ASCVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol
- Acronym
- ORION-11
- Condition
- ASCVD
- Condition
- Risk Factor, Cardiovascular
- Condition
- Elevated Cholesterol
- Intervention (Drug)
- Inclisiran Sodium
- Intervention (Drug)
- Placebo
- Lead sponsor
- The Medicines Company
Record details
- Record id
cardio:ct-nct03400800- Content hash
b6a6017a5f01ecef870eeb77d56e9bb10e567d18b73392da45909d31147133de